Physician profile

Sheilin Hamid

Tamarac, FL

NPI 1871243436

$183.82

in general payments reported to CMS, 2019-2025

6 companies · $47.21 in 2025

The $47.21 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$183.82

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Corium, LLC $59.77 2024 Azstarys
Vanda Pharmaceuticals INC. $28.89 2024 Hetlioz, Fanapt
Janssen Pharmaceuticals, INC $27.54 2025 Spravato
Otsuka America Pharmaceutical, INC. $25.44 2024 Rexulti
Almatica Pharma LLC $22.51 2024 Loreev Xr
Supernus Pharmaceuticals, INC. $19.67 2025 Qelbree

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sheilin Hamid

$183.82

in general payments reported 2019-2025

Years
2024-2025
Top company
Corium, LLC
Context
The $47.21 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/11688271/sheilin-hamid

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.